Home › Chronic Lymphocytic Leukemia › Maine
Chronic Lymphocytic Leukemia clinical trials in Maine
6 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Maine.
Cities in Maine
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
- Mid Coast Hospital, Brunswick
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- MaineHealth Maine Medical Center - Portland, Portland
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Sep 2, 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- and 9 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 105, Westbrook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 12, 2026 · NCT07582432Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- New England Cancer Specialists, Scarborough
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 21, 2026 · NCT06333262Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- New England Cancer Specialists, Scarborough
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 5, 2025 · NCT05168930From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.